New Frost & Sullivan analysis reveals that future winners will be those that can execute faster, industrialise innovation, and navigate mounting pricing and geopolitical pressures<\/i><\/p>\n
LONDON<\/span>, June 11, 2026<\/span> \/PRNewswire\/ — Frost & Sullivan’s latest analysis, Growth Opportunities in Global Pharmaceutical Industry, 2026<\/i>, finds that the pharmaceutical industry is entering a period of profound transformation as affordability mandates, patent expiries, geopolitical fragmentation, and rapid technological advances reshape the foundations of value creation.<\/p>\n According to the study, traditional drivers of success are being replaced by a new set of competitive imperatives centred on execution excellence, supply resilience, AI-enabled operations, and the ability to commercialise increasingly complex therapeutic modalities at scale.<\/p>\n “2026 marks a decisive reset for global biopharma,” said Surbhi Gupta, Industry Principal at Frost & Sullivan<\/b>. “Commercial success will depend less on historical peak-sales models and more on how quickly companies can generate evidence, secure market access, integrate innovation, and reliably deliver advanced therapies in increasingly complex operating environments.”<\/p>\n The analysis highlights five themes that will define the next phase of industry growth. Policy reforms, accelerating patent expiries, and intensifying pricing pressures are compressing traditional value-capture windows, forcing organisations to generate evidence earlier, strengthen lifecycle management strategies, and accelerate market access efforts. At the same time, deliverability is emerging as a critical source of competitive advantage, with manufacturing readiness, cold-chain integrity, quality assurance, and site-of-care preparedness becoming essential differentiators in an era of increasingly sophisticated therapies.<\/p>\n Innovation models are also evolving as pharmaceutical companies become more selective in their investments, prioritising scalable assets, high-conviction opportunities, and their ability to rapidly integrate and operationalise external innovation. Meanwhile, supply resilience has shifted from an operational concern to a strategic imperative, as governments and regulators place greater emphasis on localisation, continuity, and security of supply amid geopolitical uncertainty. Finally, artificial intelligence is moving beyond experimentation into governed, audit-ready workflows embedded across discovery, clinical operations, quality, manufacturing, and commercial functions, creating the foundations for more efficient and data-driven operating models.<\/p>\n Frost & Sullivan notes that growth opportunities are increasingly concentrated around biologics and next-generation modalities, including GLP-1 therapies, antibody-drug conjugates (ADCs), radioligand therapies, and cell and gene therapies, while surrounding ecosystems such as obesity care operating systems, specialised manufacturing capabilities, and confirmatory-ready clinical trial models offer significant whitespace opportunities.<\/p>\n The study also forecasts a divergence in growth trajectories between traditional small molecules and large molecules. While small molecules will remain the industry’s cash-flow backbone, biologics are expected to continue expanding their share of the market as companies invest in advanced therapeutic platforms and industrial-scale execution capabilities.<\/p>\n “Pharma companies can no longer treat these pressures as a series of incremental challenges,” Gupta concludes. “The organisations that thrive will be those willing to rebuild their operating models around resilience, speed, disciplined innovation, and scalable execution.”<\/p>\n To claim your complimentary extract from this Growth Opportunity Analysis, click here: https:\/\/shorturl.at\/QABlD<\/a><\/p>\n To purchase the full report, please visit our store:\u00a0Pharmaceutical Industry Growth 2026 | Frost & Sullivan<\/a><\/p>\n About Frost & Sullivan<\/b><\/p>\n Frost & Sullivan, the Transformational Growth Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation, and leadership. The company’s Growth Pipeline as a Service provides the CEO’s Growth Team with transformational strategies and best-practice models to drive the generation, evaluation, and implementation of powerful growth opportunities. For over 60 years, Frost & Sullivan has partnered with investors, corporate leaders, and governments to identify, prioritise, and execute transformational growth strategies.<\/p>\n Your Transformational Growth Journey Starts Here:\u00a0Schedule Your Growth Pipeline Dialog\u2122<\/b><\/a>\u00a0with the Frost & Sullivan team.<\/p>\n Contact: Kristina Menzefricke <\/p>\n New Frost & Sullivan analysis reveals that future winners will be those that can execute faster, industrialise innovation, and navigate mounting pricing and geopolitical pressures<\/i><\/p>\n LONDON<\/span>, June 11, 2026<\/span> \/PRNewswire\/ — Frost & Sullivan’s latest analysis, Growth Opportunities in Global Pharmaceutical Industry, 2026<\/i>, finds that the pharmaceutical industry is entering a period of profound transformation as affordability mandates, patent expiries, geopolitical fragmentation, and rapid technological advances reshape the foundations of value creation.<\/p>\n According to the study, traditional drivers of success are being replaced by a new set of competitive imperatives centred on execution excellence, supply resilience, AI-enabled operations, and the ability to commercialise increasingly complex therapeutic modalities at scale.<\/p>\n “2026 marks a decisive reset for global biopharma,” said Surbhi Gupta, Industry Principal at Frost & Sullivan<\/b>. “Commercial success will depend less on historical peak-sales models and more on how quickly companies can generate evidence, secure market access, integrate innovation, and reliably deliver advanced therapies in increasingly complex operating environments.”<\/p>\n The analysis highlights five themes that will define the next phase of industry growth. Policy reforms, accelerating patent expiries, and intensifying pricing pressures are compressing traditional value-capture windows, forcing organisations to generate evidence earlier, strengthen lifecycle management strategies, and accelerate market access efforts. At the same time, deliverability is emerging as a critical source of competitive advantage, with manufacturing readiness, cold-chain integrity, quality assurance, and site-of-care preparedness becoming essential differentiators in an era of increasingly sophisticated therapies.<\/p>\n Innovation models are also evolving as pharmaceutical companies become more selective in their investments, prioritising scalable assets, high-conviction opportunities, and their ability to rapidly integrate and operationalise external innovation. Meanwhile, supply resilience has shifted from an operational concern to a strategic imperative, as governments and regulators place greater emphasis on localisation, continuity, and security of supply amid geopolitical uncertainty. Finally, artificial intelligence is moving beyond experimentation into governed, audit-ready workflows embedded across discovery, clinical operations, quality, manufacturing, and commercial functions, creating the foundations for more efficient and data-driven operating models.<\/p>\n Frost & Sullivan notes that growth opportunities are increasingly concentrated around biologics and next-generation modalities, including GLP-1 therapies, antibody-drug conjugates (ADCs), radioligand therapies, and cell and gene therapies, while surrounding ecosystems such as obesity care operating systems, specialised manufacturing capabilities, and confirmatory-ready clinical trial models offer significant whitespace opportunities.<\/p>\n The study also forecasts a divergence in growth trajectories between traditional small molecules and large molecules. While small molecules will remain the industry’s cash-flow backbone, biologics are expected to continue expanding their share of the market as companies invest in advanced therapeutic platforms and industrial-scale execution capabilities.<\/p>\n “Pharma companies can no longer treat these pressures as a series of incremental challenges,” Gupta concludes. “The organisations that thrive will be those willing to rebuild their operating models around resilience, speed, disciplined innovation, and scalable execution.”<\/p>\n To claim your complimentary extract from this Growth Opportunity Analysis, click here: https:\/\/shorturl.at\/QABlD<\/a><\/p>\n To purchase the full report, please visit our store:\u00a0Pharmaceutical Industry Growth 2026 | Frost & Sullivan<\/a><\/p>\n About Frost & Sullivan<\/b><\/p>\n Frost & Sullivan, the Transformational Growth Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation, and leadership. The company’s Growth Pipeline as a Service provides the CEO’s Growth Team with transformational strategies and best-practice models to drive the generation, evaluation, and implementation of powerful growth opportunities. For over 60 years, Frost & Sullivan has partnered with investors, corporate leaders, and governments to identify, prioritise, and execute transformational growth strategies.<\/p>\n Your Transformational Growth Journey Starts Here:\u00a0Schedule Your Growth Pipeline Dialog\u2122<\/b><\/a>\u00a0with the Frost & Sullivan team.<\/p>\n Contact:
<\/b><\/p>\n
Marketing & Communications
Global Customer Experience, Frost & Sullivan
kristina.menzefricke@frost.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"
<\/b><\/p>\n